Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria von Qi, Yulan, Patel, Gina, Henshaw, Joshua, Gupta, Soumi, Olbertz, Joy, Larimore, Kevin, Harding, Cary O., Merilainen, Markus, Zori, Roberto, Longo, Nicola, Burton, Barbara K., Li, Mingjin, Gu, Zhonghua, Zoog, Stephen J., Weng, Haoling H., Schweighardt, Becky

Volltext

Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM) von Thomas, Janet, Levy, Harvey, Amato, Stephen, Vockley, Jerry, Zori, Roberto, Dimmock, David, Harding, Cary O., Bilder, Deborah A., Weng, Haoling H., Olbertz, Joy, Merilainen, Markus, Jiang, Joy, Larimore, Kevin, Gupta, Soumi, Gu, Zhonghua, Northrup, Hope

Volltext

Achieving efficacy in subjects with sustained pegvaliase-neutralizing antibody responses von Aryal, Madhukar, Lau, Kelly, Boyer, Ryan, Zhou, Huiyu, Abend, Johanna, Gu, Karen, Olbertz, Joy, Gupta, Soumi, Zoog, Stephen, Larimore, Kevin

Volltext

Apoptotic resistance exhibited by dexamethasone-resistant murine 7TD1 cells is controlled independently of interleukin-6 triggered signaling von Gangavarapu, Kalyan J, Olbertz, Joy L, Bhushan, Alok, Lai, James C. K, Daniels, Christopher K

Volltext

Of mice and men: Plasma phenylalanine reduction in PKU corrects neurotransmitter pathways in the brain von Berguig, Geoffrey Y., Martin, Nathan T., Creer, Athena Y., Xie, Lin, Zhang, Lening, Murphy, Ryan, Pacheco, Glenn, Bullens, Sherry, Olbertz, Joy, Weng, Haoling H.

Volltext

Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials von Gupta, Soumi, Lau, Kelly, Harding, Cary O., Shepherd, Gillian, Boyer, Ryan, Atkinson, John P., Knight, Vijaya, Olbertz, Joy, Larimore, Kevin, Gu, Zhonghu, Li, Mingjin, Rosen, Orli, Zoog, Stephen J., Weng, Haoling H., Schweighardt, Becky

Volltext

Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trialsResearch in context von Soumi Gupta, Kelly Lau, Cary O. Harding, Gillian Shepherd, Ryan Boyer, John P. Atkinson, Vijaya Knight, Joy Olbertz, Kevin Larimore, Zhonghu Gu, Mingjin Li, Orli Rosen, Stephen J. Zoog, Haoling H. Weng, Becky Schweighardt

Volltext